Bladder cancer is the 9th leading cause of cancer, and is considered one of the most expensive cancers to live with due to long-term surveillance and treatments. Clinically, there are only limited options for bladder cancer management and no new bladder-cancer specific treatment has been approved in more than 30 years. Bladder cancer is an interesting model for studies of interactions of germline and somatic genetic variations with environmental factors such as smoking and exposure to occupational and industrial pollutants.
This group will bring together NCI investigators, both from CCR and DCEG who are working on different aspects of bladder cancer – genetics, epigenetics, epidemiology and treatment. The Bladder Cancer Interest Group (BCIG) organizes bi-monthly meetings with presentations by NIH researchers on ongoing studies and latest advancements in the field.